Neuromuscular Agents

"Neuromuscular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.

Descriptor ID	D009465
MeSH Number(s)	D27.505.696.663.700
Concept/Terms	Neuromuscular Agents Neuromuscular Agents Agents, Neuromuscular Skeletal Muscle Relaxants Skeletal Muscle Relaxants Muscle Relaxants, Skeletal Relaxants, Skeletal Muscle Neuromuscular Effect Neuromuscular Effect Effect, Neuromuscular Neuromuscular Effects Effects, Neuromuscular

Below are MeSH descriptors whose meaning is more general than "Neuromuscular Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Peripheral Nervous System Agents [D27.505.696.663]
Neuromuscular Agents [D27.505.696.663.700]

Below are MeSH descriptors whose meaning is related to "Neuromuscular Agents".

Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neuromuscular Agents" by people in this website by year, and whether "Neuromuscular Agents" was a major or minor topic of these publications.

Bar chart showing 53 publications over 17 distinct years, with a maximum of 5 publications in 2003 and 2004 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	3	2	5
2004	4	1	5
2005	3	1	4
2006	2	1	3
2008	3	0	3
2009	3	0	3
2010	0	1	1
2011	1	1	2
2012	0	1	1
2013	2	1	3
2015	2	0	2
2016	2	0	2
2018	3	1	4
2019	3	1	4
2020	5	0	5
2021	2	0	2
2024	0	4	4

Below are the most recent publications written about "Neuromuscular Agents" by people in Profiles.

Gollomp SM, Khalifian S, Gokhale S. Mitigating Immunogenicity by Coordinating Botulinum Toxin Treatments Between Aesthetics and Therapeutics. Dermatol Surg. 2024 Sep 01; 50(9S):S35-S37.

View in: PubMed
Heckert K, Biering-S?rensen B, B?umer T, Khan O, Pagan F, Paulin M, Stitik T, Verduzco-Gutierrez M, Reebye R. Delphi Analysis: Optimizing Anatomy Teaching and Ultrasound Training for Botulinum Neurotoxin Type A Injection in Spasticity and Dystonia. Toxins (Basel). 2024 Aug 21; 16(8).

View in: PubMed
Pozo-Rosich P, Alpuente A, Silberstein SD, Burstein R. Insights from 25?years of onabotulinumtoxinA in migraine - mechanisms and management. Nat Rev Neurol. 2024 09; 20(9):555-568.

View in: PubMed
Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache. 2024 Jul-Aug; 64(7):838-848.

View in: PubMed
Esquenazi A, Ayyoub Z, Verduzco-Gutierrez M, Maisonobe P, Otto J, Patel AT. AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol. Adv Ther. 2021 11; 38(11):5623-5633.

View in: PubMed
Esquenazi A, Bavikatte G, Bandari DS, Jost WH, Munin MC, Tang SFT, Largent J, Adams AM, Zuzek A, Francisco GE. Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity. PM R. 2021 10; 13(10):1079-1093.

View in: PubMed
Hjelm N, Crippen M, Azizzadeh B. Long-Term Changes in the Treatment Pattern of Botulinum Toxin A Injections for Postfacial Paralysis Synkinesis Following Modified Selective Neurectomy. Facial Plast Surg Aesthet Med. 2021 May-Jun; 23(3):234-235.

View in: PubMed
Sergott RC, Amorelli GM, Baranello G, Barreau E, Beres S, Kane S, Mercuri E, Orazi L, SantaMaria M, Tremolada G, Santarsiero D, Waskowska A, Yashiro S, Denk N, F?rst-Recktenwald S, Gerber M, Gorni K, Jaber B, Jacobsen B, Mueller L, Nave S, Scalco RS, Marzoli SB. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol. 2021 01; 8(1):54-65.

View in: PubMed
Esquenazi A, Brashear A, Deltombe T, Rudzinska-Bar M, Krawczyk M, Skoromets A, O'Dell MW, Grandoulier AS, Vilain C, Picaut P, Gracies JM. The Effect of Repeated abobotulinumtoxinA (Dysport?) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury. PM R. 2021 05; 13(5):488-495.

View in: PubMed
Esquenazi A, Stoquart G, Hedera P, Jacinto LJ, Dimanico U, Constant-Boyer F, Brashear A, Grandoulier AS, Vilain C, Picaut P, Gracies JM. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial. PM R. 2020 09; 12(9):853-860.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement